MEHMET EREN 
Complete Metabolic Remission of Colon Carcinoma Without Conventional Therapy: A Case Report on the Use of Curcumin-Based Supplement (Zarenca)

Abstract
We report the case of a 73-year-old male diagnosed with colon adenocarcinoma who achieved complete metabolic remission without undergoing chemotherapy or radiotherapy. Instead, the patient received a curcumin-based natural supplement known as Zarenca over the course of eight months. Serial PET/CT imaging demonstrated the disappearance of all hypermetabolic lesions, including primary colonic and prostatic lesions. This case suggests that curcumin-based therapy may play a potential role in managing certain malignancies and warrants further investigation.

Introduction
Colorectal cancer is one of the most common malignancies worldwide and is typically managed with surgical resection, chemotherapy, and/or radiotherapy. Despite advances in treatment, recurrence and metastasis remain major challenges. Curcumin, a natural polyphenol derived from turmeric (Curcuma longa), has demonstrated anti-inflammatory, antioxidant, and anticancer properties in numerous preclinical studies. However, clinical evidence of curcumin-induced complete remission remains scarce.

Case Presentation
A 73-year-old male presented to Süleyman Demirel University Hospital in early January 2023 with symptoms suggestive of colorectal malignancy. FDG-PET/CT conducted on January 5, 2023, revealed:

A hypermetabolic lesion in the ascending colon measuring approximately 2 × 3 cm (SUVmax: 7.65), interpreted as a primary tumor.

A hypermetabolic prostatic lesion (SUVmax: 8.02), suspicious for neoplasia.

A hypodense lesion in liver segment VI/VII, suggestive of early metastasis.

Bilateral inguinal lymph nodes considered benign/reactive.

The patient opted not to receive chemotherapy or radiotherapy. Instead, beginning January 2023, he initiated a regimen of a plant-based supplement, Zarenca, containing high-bioavailability curcumin and other natural anti-inflammatory compounds. He remained compliant with the daily dosing protocol.

A follow-up PET/CT scan dated September 5, 2023, showed:

Complete resolution of FDG uptake in the colon, prostate, liver, and lymphatic regions.

No residual hypermetabolic lesions detected in the entire body.

The findings were interpreted as complete metabolic response according to the evaluating nuclear medicine specialists.

The patient remained clinically stable and asymptomatic as of the time of reporting (July 2025).

Discussion
Curcumin’s anticancer mechanisms include inhibition of nuclear factor-κB (NF-κB), suppression of STAT3 activation, modulation of apoptotic pathways, and reduction of inflammatory cytokines. While numerous in vitro and animal studies have demonstrated its efficacy, translation to human cancer remission is rare and anecdotal. This case contributes novel human data, particularly in the context of curcumin use without conventional therapy.

It is also noteworthy that both colon and prostate lesions exhibited significant FDG uptake prior to treatment and achieved complete resolution, suggesting systemic benefit. Although spontaneous remission cannot be entirely ruled out, the temporal association and lack of other interventions strengthen the link to curcumin supplementation.

Conclusion
This report documents a rare case of complete metabolic remission of colorectal cancer in a patient treated solely with a curcumin-based supplement. The findings highlight the potential role of phytochemicals in cancer management and emphasize the need for further controlled studies.

Informed Consent
Written informed consent was obtained from the patient for publication of this case report and accompanying images.

References(To be added: references on curcumin and colorectal cancer studies)